Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery

Cambridge, Mass. –February 20, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced further growth of their leadership team with the appointment of Christopher Moxham, Ph.D. as senior vice president of discovery.

Read more